Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.

[1]  Swati Bhattacharyya,et al.  Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis , 2010, Current opinion in rheumatology.

[2]  J. Varga,et al.  Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management , 2010, Arthritis research & therapy.

[3]  D. Judge,et al.  Mutations in Fibrillin-1 Cause Congenital Scleroderma: Stiff Skin Syndrome , 2010, Science Translational Medicine.

[4]  J. Bourke,et al.  Effects of PPARγ ligands on TGF-β1-induced epithelial-mesenchymal transition in alveolar epithelial cells , 2010, Respiratory research.

[5]  V. Nizet,et al.  Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis , 2010, Proceedings of the National Academy of Sciences.

[6]  Oliver Eickelberg,et al.  WNT signaling in lung disease: a failure or a regeneration signal? , 2010, American journal of respiratory cell and molecular biology.

[7]  S. Narumiya,et al.  Prostaglandin F2α receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-β , 2009, Nature Medicine.

[8]  J. Sznajder,et al.  Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[9]  W. Tourtellotte,et al.  Cell Injury , Repair , Aging and Apoptosis Essential Roles for Early Growth Response Transcription Factor Egr-1 in Tissue Fibrosis and Wound Healing , 2010 .

[10]  Y. Barak,et al.  Peroxisome proliferator‐activated receptor‐γ abrogates Smad‐dependent collagen stimulation by targeting the p300 transcriptional coactivator , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  M. Kapoor,et al.  Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. , 2009, Arthritis and rheumatism.

[12]  Kevin D Cooper,et al.  Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. , 2009, The Journal of investigative dermatology.

[13]  P. Weinreb,et al.  Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). , 2009, The American journal of pathology.

[14]  W. Seeger,et al.  WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. , 2009, The Journal of clinical investigation.

[15]  K. Huxlin,et al.  Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. , 2009, American journal of respiratory cell and molecular biology.

[16]  Minghua Wu,et al.  A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate , 2009, Oncogene.

[17]  B. Beutler.  TLRs and innate immunity. , 2009, Blood.

[18]  I. Fajardy,et al.  Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. , 2009, Arthritis and rheumatism.

[19]  F. Arnett,et al.  Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. , 2008, Arthritis and rheumatism.

[20]  Steven K. Huang,et al.  Translating Basic Research into Clinical PracticeEicosanoid Lipid Mediators in Fibrotic Lung Diseases: Ready for Prime Time? , 2008 .

[21]  D. Pritchard,et al.  Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. , 2008, Arthritis and rheumatism.

[22]  L. Klein-Hitpass,et al.  The first five years of the Wnt targetome. , 2008, Cellular signalling.

[23]  R. Kumar,et al.  Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. , 2008, The Journal of investigative dermatology.

[24]  N. Kaminski,et al.  Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs? , 2008, PLoS medicine.

[25]  J. Varga,et al.  Fibrosis in systemic sclerosis. , 2008, Rheumatic diseases clinics of North America.

[26]  Alisa Opar.  Amidst challenges, UK research hub moves closer to relocation , 2008, Nature Medicine.

[27]  J. Wain,et al.  The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak , 2008, Nature Medicine.

[28]  K. Kimura,et al.  Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. , 2007, The Journal of clinical investigation.

[29]  John Varga,et al.  The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis , 2007, Journal of cellular physiology.

[30]  R. Gay,et al.  Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. , 2007, Arthritis and rheumatism.

[31]  R. Lafyatis,et al.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. , 2007, Arthritis and rheumatism.

[32]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[33]  L. Crofford,et al.  Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[34]  K. Miyake.  Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. , 2007, Seminars in immunology.

[35]  C. Chizzolini.  Update on pathophysiology of scleroderma with special reference to immunoinflammatory events , 2007, Annals of medicine.

[36]  R. Schwabe,et al.  TLR4 enhances TGF-beta signaling and hepatic fibrosis. , 2007, Nature medicine.

[37]  J. Shearstone,et al.  Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. , 2006, Arthritis and rheumatism.

[38]  Scott Bowes,et al.  Intracellular TGF-β Receptor Blockade Abrogates Smad-Dependent Fibroblast Activation In Vitro and In Vivo , 2006 .

[39]  J. Varga,et al.  The Early-Immediate Gene EGR-1 Is Induced by Transforming Growth Factor-β and Mediates Stimulation of Collagen Gene Expression* , 2006, Journal of Biological Chemistry.

[40]  M. Mayes,et al.  Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. , 2006, Arthritis and rheumatism.

[41]  Xiaodong Zhou,et al.  Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. , 2006, Rheumatology.

[42]  Yunliang Chen,et al.  Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. , 2006, Arthritis and rheumatism.

[43]  R. Homer,et al.  Role of Early Growth Response-1 (Egr-1) in Interleukin-13-induced Inflammation and Remodeling* , 2006, Journal of Biological Chemistry.

[44]  M. Jinnin,et al.  Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. , 2006, Rheumatology.

[45]  P. Ye,et al.  Effect of Aging on the Expression of Peroxisome Proliferator-Activated Receptor γ and the Possible Relation to Insulin Resistance , 2006, Gerontology.

[46]  Scott Bowes,et al.  Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. , 2006, The Journal of investigative dermatology.

[47]  M. Jinnin,et al.  Increased Expression of Integrin αvβ3 Contributes to the Establishment of Autocrine TGF-β Signaling in Scleroderma Fibroblasts1 , 2005, The Journal of Immunology.

[48]  J. Varga,et al.  Scleroderma: from cell and molecular mechanisms to disease models. , 2005, Trends in immunology.

[49]  H. Ihn.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix , 2005, Current rheumatology reports.

[50]  M. Jinnin,et al.  Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. , 2005, Journal of immunology.

[51]  C. Daniels,et al.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.

[52]  J. Pannu,et al.  Recent advances in fibroblast signaling and biology in scleroderma , 2004, Current opinion in rheumatology.

[53]  Ajamete Kaykas,et al.  WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.

[54]  E. Adamson,et al.  Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. , 2004, Molecular cell.

[55]  H. Ihn,et al.  Increased Expression Levels of Integrin αvβ5 on Scleroderma Fibroblasts , 2004 .

[56]  A. Ghosh,et al.  Disruption of transforming growth factor β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator–activated receptor γ , 2004 .

[57]  H. Ihn,et al.  Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. , 2004, The Journal of clinical investigation.

[58]  Randall T Moon,et al.  WNT and beta-catenin signalling: diseases and therapies. , 2004, Nature reviews. Genetics.

[59]  B. Barna,et al.  Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. , 2004, American journal of respiratory cell and molecular biology.

[60]  A. Ghosh,et al.  Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. , 2004, Arthritis and rheumatism.

[61]  H. Ihn,et al.  Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. , 2004, The American journal of pathology.

[62]  David Botstein,et al.  Systemic and cell type-specific gene expression patterns in scleroderma skin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  V. Poletti,et al.  Aberrant Wnt/ (cid:1) -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis , 2003 .

[64]  V. Poletti,et al.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. , 2003, The American journal of pathology.

[65]  J. Varga.  Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. , 2002, Arthritis and rheumatism.

[66]  G. Striker,et al.  Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation , 2002 .

[67]  G. Striker,et al.  Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. , 2002, American journal of physiology. Renal physiology.

[68]  H. Ihn,et al.  Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor β receptors , 2001 .

[69]  K. Yamane,et al.  Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. , 2001, Arthritis and rheumatism.

[70]  T. Willson,et al.  Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation* , 2000, The Journal of Biological Chemistry.

[71]  T. Krieg,et al.  Fibroblast-matrix interactions in wound healing and fibrosis. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[72]  A. Ghosh,et al.  Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivators , 2000, Oncogene.

[73]  J. Varga,et al.  Interaction of Smad3 with a proximal smad‐binding element of the human α2(I) procollagen gene promoter required for transcriptional activation by TGF‐β , 2000 .

[74]  S. J. Chen,et al.  Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. , 2000, Journal of cellular physiology.

[75]  S. J. Chen,et al.  Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. , 1999, The Journal of investigative dermatology.

[76]  E. Leroy.  CONNECTIVE TISSUE SYNTHESIS BY SCLERODERMA SKIN FIBROBLASTS IN CELL CULTURE , 1972, The Journal of experimental medicine.

[77]  E. CARwni LEROYwith,et al.  Increased Collagen Synthesis by Scleroderma Skin Fibroblasts In Vitro A POSSIBLE DEFECT IN THE REGULATION OR ACTIVATION OF THE SCLERODERMA FIBROBLAST , 2022 .